Continuity Biosciences Welcomes Josephine Torrente and Joseph DeSimone to Its Board of Directors
Continuity Biosciences, a pioneering company in next-generation combination product drug delivery, recently announced the appointment of two influential leaders to its board of directors: Josephine M. Torrente and Dr. Joseph M. DeSimone. These strategic appointments reflect the company's commitment to enhancing its mission of advancing transformational drug delivery technologies with top-tier regulatory expertise and materials science innovation.
Josephine M. Torrente, currently the Director at Hyman, Phelps & McNamara, P.C., the largest FDA regulatory law firm in the United States, brings over 30 years of experience advising pharmaceutical and biotechnology firms on regulatory strategies, product development, and lifecycle management. Torrente's extensive regulatory knowledge is poised to guide Continuity's clinical development and FDA engagement strategies as the company expands its product portfolio.
On the other hand, Dr. Joseph M. DeSimone serves as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. A distinguished figure in the field, DeSimone is a winner of the National Medal of Technology and Innovation, holds over 200 patents, and has authored more than 350 scientific publications. His entrepreneurial ventures include co-founding Carbon, known for its development of Continuous Liquid Interface Production (CLIP) 3D printing technology, and founding Focal Medical, which Continuity has acquired. DeSimone's expertise in materials science, digital manufacturing, and drug delivery aligns seamlessly with Continuity's focus on localized and precision therapies.
Bob Whitehead, co-founder and executive chairman of Continuity Biosciences, expressed enthusiasm about the new appointments, stating, "It is an honor to welcome Josephine and Joe to our board of directors. Josephine's regulatory insight and clarity are unparalleled, while Joe is not only a visionary in drug delivery but also a trusted partner in our initiatives with Focal Medical and PinPrint. Their experience will be crucial as we continue to expand our programs and create long-term value."
With the addition of Torrente and DeSimone, Continuity's board strengthens its leadership, which already includes co-founders Bob Whitehead and Ramakrishna Venugopalan, PhD, MBA, as well as other esteemed members like Monica Reed, MD, Mike Fowler, and Allen Weiss. Venugopalan has previously led combination product development at AbbVie, contributing to its flagship therapies such as Skyrizi and the recently launched Vyalev. Mike Fowler is the CEO of Affordable Housing Partners, Inc., a subsidiary of Berkshire Hathaway, while Allen Weiss held the position of CEO of Global Operations for Walt Disney Parks and Resorts. Additionally, Monica Reed serves as the CEO of AdventHealth at UChicago Medicine, overseeing the strategic development and growth of the Lakes Region health system, comprising four hospitals and over 50 care centers.
Founded in 2024, Continuity Biosciences specializes in developing advanced platforms for the delivery of biological products and complex therapies, emphasizing precise targeting and adjustable release mechanisms. With operational hubs in Houston, Texas, Raleigh, North Carolina, Bradenton, Florida, and Turin, Italy, the company’s product portfolio covers oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions like Focal Medical and targeted investments like PinPrint, Continuity is building a distinctive platform aimed at transforming the delivery of complex therapies.
For further insights into Continuity Biosciences, its product offerings, and future prospects, stay tuned as the company embarks on this exciting new chapter in its journey toward innovative drug delivery solutions.
Josephine M. Torrente, currently the Director at Hyman, Phelps & McNamara, P.C., the largest FDA regulatory law firm in the United States, brings over 30 years of experience advising pharmaceutical and biotechnology firms on regulatory strategies, product development, and lifecycle management. Torrente's extensive regulatory knowledge is poised to guide Continuity's clinical development and FDA engagement strategies as the company expands its product portfolio.
On the other hand, Dr. Joseph M. DeSimone serves as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. A distinguished figure in the field, DeSimone is a winner of the National Medal of Technology and Innovation, holds over 200 patents, and has authored more than 350 scientific publications. His entrepreneurial ventures include co-founding Carbon, known for its development of Continuous Liquid Interface Production (CLIP) 3D printing technology, and founding Focal Medical, which Continuity has acquired. DeSimone's expertise in materials science, digital manufacturing, and drug delivery aligns seamlessly with Continuity's focus on localized and precision therapies.
Bob Whitehead, co-founder and executive chairman of Continuity Biosciences, expressed enthusiasm about the new appointments, stating, "It is an honor to welcome Josephine and Joe to our board of directors. Josephine's regulatory insight and clarity are unparalleled, while Joe is not only a visionary in drug delivery but also a trusted partner in our initiatives with Focal Medical and PinPrint. Their experience will be crucial as we continue to expand our programs and create long-term value."
With the addition of Torrente and DeSimone, Continuity's board strengthens its leadership, which already includes co-founders Bob Whitehead and Ramakrishna Venugopalan, PhD, MBA, as well as other esteemed members like Monica Reed, MD, Mike Fowler, and Allen Weiss. Venugopalan has previously led combination product development at AbbVie, contributing to its flagship therapies such as Skyrizi and the recently launched Vyalev. Mike Fowler is the CEO of Affordable Housing Partners, Inc., a subsidiary of Berkshire Hathaway, while Allen Weiss held the position of CEO of Global Operations for Walt Disney Parks and Resorts. Additionally, Monica Reed serves as the CEO of AdventHealth at UChicago Medicine, overseeing the strategic development and growth of the Lakes Region health system, comprising four hospitals and over 50 care centers.
Founded in 2024, Continuity Biosciences specializes in developing advanced platforms for the delivery of biological products and complex therapies, emphasizing precise targeting and adjustable release mechanisms. With operational hubs in Houston, Texas, Raleigh, North Carolina, Bradenton, Florida, and Turin, Italy, the company’s product portfolio covers oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions like Focal Medical and targeted investments like PinPrint, Continuity is building a distinctive platform aimed at transforming the delivery of complex therapies.
For further insights into Continuity Biosciences, its product offerings, and future prospects, stay tuned as the company embarks on this exciting new chapter in its journey toward innovative drug delivery solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.